Buchumschlag

Nebenwirkungsmanagement in der Immunonkologie

<p>The immune oncological treatment approach uses immune checkpoint inhibitors to prevent tumor cells from shutting down the immune system, and thus from escaping immune response. Following the clinical success of immune checkpoint inhibitors, the number of approved immune oncological therapie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Reinmuth, Niels (VerfasserIn) , Bitzer, Michael (VerfasserIn) , Deschler-Baier, Barbara (VerfasserIn) , Fischer, Jürgen (VerfasserIn) , Kuon, Jonas (VerfasserIn) , Leipe, Jan (VerfasserIn) , Rawluk, Justyna (VerfasserIn) , Schulz, Christian (VerfasserIn) , Heußel, Claus Peter (VerfasserIn) , Schultheiß, Michael (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Deutsch
Veröffentlicht: 2019
In: Deutsche medizinische Wochenschrift
Year: 2019, Jahrgang: 144, Heft: 05, Pages: 346-353
ISSN:1439-4413
DOI:10.1055/a-0739-8194
Online-Zugang:Verlag, Volltext: https://doi.org/10.1055/a-0739-8194
Verlag, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-0739-8194
Volltext
Verfasserangaben:Niels Reinmuth, Michael Bitzer, Barbara Deschler-Baier, Jürgen R. Fischer, Jonas Kuon, Jan Leipe, Justyna Rawluk, Christian Schulz, Claus Peter Heußel, Michael Schultheiß
Beschreibung
Zusammenfassung:<p>The immune oncological treatment approach uses immune checkpoint inhibitors to prevent tumor cells from shutting down the immune system, and thus from escaping immune response. Following the clinical success of immune checkpoint inhibitors, the number of approved immune oncological therapies continues to increase. Response rates and overall survival with anti-PD-1/PD-L1 and CTLA-4 blockade could be further improved by combining both treatment approaches. However, checkpoint inhibition is associated with a unique spectrum of side effects termed immune-related adverse events. These typically occur 3 to 6 months after treatment start and resolve with adequate management procedures if detected early on. Therefore, profound patient education, sensitizing and monitoring are mandatory. We describe in this article selected frequent and rare adverse events that are clinically relevant. Furthermore, using case reports, interdisciplinary experts share their practice-based experience in the management of frequent pneumonic, endocrine, and gastro-intestinal immune-related adverse events.</p>
Beschreibung:Gesehen am 09.05.2019
Beschreibung:Online Resource
ISSN:1439-4413
DOI:10.1055/a-0739-8194

Ähnliche Einträge